Background: Recent studies suggest a relationship between atherosclerotic disease and osteoporosis. The aim of the study was to investigate whether bone mineral density (BMD) was prospectively related to stroke and death. Methods: BMD (g/cm2) was measured in 4,302 men and women (mean age 59 years, range 40–75) at baseline. The main outcome measures included validated strokes and death. Results: After a mean follow-up time of 5.6 years (range 0–15.8 years), 139 strokes were registered and 224 subjects had died. After adjustment for age, sex and body mass index, decreased femoral neck BMD and osteoporosis were found to be independent predictors of stroke (hazard ratio, HR, for each standard deviation decrease in BMD = 1.23, 95% CI = 1.01–1.49, and HR for osteoporosis = 1.92, 95% CI = 1.11–3.30). After adjustment for the same variables, the risk of death during follow-up was related to femoral neck BMD (HR = 1.41, 95% CI = 1.21–1.64) and osteoporosis at baseline (HR = 2.05, 95% CI = 1.28–3.29). Adjustment also for smoking, hypertension, hyperlipidemia and diabetes did not change any of these results. Conclusions: We found that decreased BMD as well as osteoporosis of the femoral neck are independently associated with stroke and death. Given the impact of osteoporosis and stroke on morbidity and mortality, this relationship is of high interest for further studies.

Keywords:
Bone density, Osteoporosis, Stroke, Risk of death
1.
Riggs BL, Melton LJ, 3rd: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S–511S.
2.
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037.
3.
Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–650.
4.
Lerner DJ, Kannel WB: Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383–390.
5.
Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, Taubert KA: Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the stroke council and the council on clinical cardiology of the American Heart Association/American Stroke Association. Circulation 2003;108:1278–1290.
6.
Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto H, Kumakura H, Takayama Y, Kanda T, Murakami M, Kurabayashi M: Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circ J 2007;71:1555–1559.
7.
Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV: Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998;62:209–213.
8.
Sinnott B, Syed I, Sevrukov A, Barengolts E: Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int 2006;78:195–202.
9.
Tamaki J, Iki M, Hirano Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H: Low bone mass is associated with carotid atherosclerosis in postmenopausal women: The Japanese Population-Based Osteoporosis (JPOS) cohort study. Osteoporos Int 2009;20:53–60.
10.
Hofbauer LC, Brueck CC, Singh SK, Dobnig H: Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007;22:1317–1328.
11.
Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K: Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 2009;24:241–250.
12.
Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. Lancet 2008;371:1612–1623.
13.
Dobkin BH: Clinical practice. Rehabilitation after stroke. N Engl J Med 2005;352:1677–1684.
14.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 1995;332:767–773.
15.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321–333.
16.
Stegmayr B, Lundberg V, Asplund K: The events registration and survey procedures in the northern Sweden MONICA project. Scand J Public Health Suppl 2003;61:9–17.
17.
Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S: Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998;16:171–176.
18.
Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929–1936.
19.
Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR: Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke 1993;24:940–946.
20.
Browner WS, Seeley DG, Vogt TM, Cummings SR: Non-trauma mortality in elderly women with low bone mineral density. Study of osteoporotic fractures research group. Lancet 1991;338:355–358.
21.
Mussolino ME, Madans JH, Gillum RF: Bone mineral density and stroke. Stroke 2003;34:e20–e22.
22.
Jorgensen L, Engstad T, Jacobsen BK: Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke 2001;32:47–51.
23.
Trivedi DP, Khaw KT: Bone mineral density at the hip predicts mortality in elderly men. Osteoporos Int 2001;12:259–265.
24.
Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE: Bone mineral density and mortality in elderly men and women: The Rotterdam Study. Bone 2002;30:643–648.
25.
Kawano K, Ogata N, Chiano M, Molloy H, Kleyn P, Spector TD, Uchida M, Hosoi T, Suzuki T, Orimo H, Inoue S, Nabeshima Y, Nakamura K, Kuro-o M, Kawaguchi H: Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 2002;17:1744–1751.
26.
Imamura A, Okumura K, Ogawa Y, Murakami R, Torigoe M, Numaguchi Y, Murohara T: Klotho gene polymorphism may be a genetic risk factor for atherosclerotic coronary artery disease but not for vasospastic angina in Japanese. Clin Chim Acta 2006;371:66–70.
27.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319.
28.
Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192–1194.
29.
Strand M, Soderstrom I, Wiklund PG, Hallmans G, Weinehall L, Soderberg S, Olsson T: Polymorphisms at the osteoprotegerin and interleukin-6 genes in relation to first-ever stroke. Cerebrovasc Dis 2007;24:418–425.
30.
Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–809.
31.
Ding C, Parameswaran V, Udayan R, Burgess J, Jones G: Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008;93:1952–1958.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.